MD-60 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Md-60, and what generic alternatives are available?
Md-60 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in MD-60 is diatrizoate meglumine; diatrizoate sodium. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Md-60
A generic version of MD-60 was approved as diatrizoate meglumine; diatrizoate sodium by ADAPTIS on June 27th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MD-60?
- What are the global sales for MD-60?
- What is Average Wholesale Price for MD-60?
Summary for MD-60
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | MD-60 at DailyMed |
US Patents and Regulatory Information for MD-60
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | MD-60 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 087074-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
